Five Prime Therapeutics Inc. has agreed to pay Inhibrx LLC $10 million for global rights to use antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR) either alone or, more likely in combination with potential immuno-oncology therapies, such as its own phase I FPA-008, targeting tumor-associated macrophages.